Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) shares traded down 10.1% during mid-day trading on Wednesday following a dissappointing earnings announcement. The company traded as low as $19.73 and last traded at $19.76. 1,460,632 shares were traded during mid-day trading, an increase of 3% from the average session volume of 1,423,772 shares. The stock […]
Alpha DNA Investment Management LLC purchased a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 33,552 shares of the biopharmaceutical company’s stock, valued at approximately $1,081,000. Other hedge funds […]
Essex Investment Management Co. LLC increased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 59.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,613 shares of the biopharmaceutical company’s stock after acquiring an […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) CFO Tobin Schilke sold 1,701 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $25.04, for a total value of $42,593.04. Following the completion of the transaction, the chief financial officer now owns 79,896 shares of […]
Waypoint Capital Advisors LLC raised its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) by 68.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 90,989 shares of the biopharmaceutical company’s stock after acquiring an additional 37,000 shares during the quarter. Waypoint Capital Advisors LLC’s holdings in Revance Therapeutics were worth $2,930,000 […]